SUCLA2 encodes the β subunit of ADP-forming succinyl-CoA synthetase (SCS), also known as succinate-CoA ligase ADP-forming GDP form. This mitochondrial enzyme catalyzes a critical step in the tricarboxylic acid cycle (TCA cycle) and is essential for cellular ATP production. SUCLA2 forms a heterodimer with the α subunit (SUCLG1) to create the ADP-forming SCS isoform, which is predominantly expressed in tissues with high ATP demand, including brain, heart, and skeletal muscle. [1]
Mutations in SUCLA2 cause mitochondrial DNA depletion syndrome (MTDPS), a severe autosomal recessive disorder characterized by profound mitochondrial dysfunction, encephalomyopathy, and early-onset neurodegeneration. The gene is also implicated in Alzheimer's Disease (AD) and Parkinson's Disease through its role in mitochondrial energy metabolism and nucleotide homeostasis. [2]
| Property | Value |
|---|---|
| Gene Symbol | SUCLA2 |
| Full Name | Succinate-CoA Ligase ADP Forming Subunit Beta |
| Aliases | SCS-β, SUCL-BETA, Beta-succinyl CoA synthetase |
| Chromosomal Location | 13q14.2 |
| NCBI Gene ID | 8802 |
| OMIM | 603921 |
| Ensembl ID | ENSG00000147576 |
| UniProt | P53999 |
| Protein Class | Mitochondrial Matrix Enzyme |
| Associated Diseases | Alzheimer Disease, Mitochondrial Encephalomyopathy, Cardiomyopathy, Deafness |
ADP-forming succinyl-CoA synthetase (SCS) is a heterodimeric enzyme:
α Subunit (SUCLG1):
β Subunit (SUCLA2):
The α-β heterodimer is the minimal functional unit. Assembly occurs in the mitochondrial matrix, requiring proper mitochondrial protein import and folding. [3]
The SCS reaction proceeds through a two-step mechanism:
Step 1: Succinyl-CoA Binding and Thiolysis
Step 2: Nucleotide Addition (Phosphorylation)
The overall reaction:
Succinyl-CoA + ADP + Pi ↔ Succinate + ATP + CoA
This is one of only two ATP-producing steps in the TCA cycle, making SCS essential for aerobic energy metabolism. [4]
The SUCLA2-containing SCS isoform has distinct properties:
| Property | ADP-Forming (SUCLA2) | GDP-Forming (SUCLG2) |
|---|---|---|
| Nucleotide | ADP/ATP | GDP/GTP |
| Distribution | Predominant in heart, brain | Predominant in liver, kidney |
| Tissue Specificity | High energy demand tissues | Metabolic tissues |
| Pathogenic Variants | More common | Less common |
The relative ratios of ADP-forming to GDP-forming isoforms vary by tissue, reflecting different metabolic requirements. In the brain, the ADP-forming isoform predominates, consistent with the high ATP demands of neurons. [3:1]
The SUCLA2 protein contains:
N-terminal Mitochondrial Targeting Sequence (MTS): Cleaved upon mitochondrial import (~30 amino acids)
Nucleotide-Binding Domain (NBD): Rossmann-like fold that binds ADP/ATP
CoA-binding Domain: On the SUCLG1 α subunit
Inter-subunit Interface: Extensive contact between α and β subunits, essential for stability
Crystal structures reveal that the β subunit undergoes conformational changes during the catalytic cycle, alternating between open and closed states for nucleotide binding and release. [3:2]
SUCLA2 is centrally positioned in mitochondrial metabolism:
Entry Point: Succinyl-CoA, the substrate for SCS, is produced from:
Exit Points: The products of SCS catalysis feed into:
The ATP produced by SCS is directly available for:
In neurons, this localized ATP production is critical for:
SUCLA2 deficiency leads to impaired mitochondrial respiration and reduced ATP production, particularly in tissues with high energy demands. [5]
Beyond energy production, SCS connects to nucleotide metabolism:
ATP/ADP Pool Maintenance:
mtDNA Maintenance:
Deoxyribonucleotide Synthesis:
Biallelic mutations in SUCLA2 cause mitochondrial DNA depletion syndrome type V (MTDPS V), also known as "mitochondrial encephalomyopathy with methylmalonic aciduria":
Clinical Features:
Biochemical Hallmarks:
Genetics: Autosomal recessive inheritance. Over 30 pathogenic variants identified:
Pathogenesis: SUCLA2 mutations lead to:
SUCLA2 expression and function are altered in Alzheimer's disease:
Expression Changes: Post-mortem AD brains show:
Mechanistic Links:
Therapeutic Implications: Enhancing SUCLA2 expression or activity could:
SUCLA2 may play protective roles in dopaminergic neurons:
Mitochondrial Protection: In substantia nigra dopaminergic neurons:
Potential Mechanisms:
Genetic Associations: While SUCLA2 is not a major PD risk gene, variants may modify disease severity or progression in some populations.
SUCLA2 mutations can cause cardiomyopathy as part of mitochondrial disease:
Hearing Loss: Sensorineural deafness is common in SUCLA2 deficiency:
Epilepsy: SUCLA2-related encephalopathy includes:
Neurons have exceptionally high energy requirements:
Resting Potential: The Na⁺/K⁺ ATPase consumes ~70% of neuronal ATP
Synaptic Activity: Neurotransmitter cycling requires:
Signal Transduction: Second messenger synthesis:
SUCLA2 supports these demands through localized ATP production in the mitochondrial matrix near areas of high consumption. [5:1]
Mitochondria buffer intracellular calcium:
In neurons:
SUCLA2 function is calcium-responsive, providing metabolic support for calcium-dependent signaling. [5:2]
Synaptic terminals have specialized energy requirements:
Presynaptic Terminals:
Postsynaptic Densities:
Implications of Dysfunction: SUCLA2 deficiency leads to:
This parallels the synaptic deficits seen in early AD and PD. [5:3]
AAV-mediated SUCLA2 delivery is being explored:
Challenges:
CoQ10 and MitoQ: Antioxidants supporting mitochondrial function
L-Carnitine: Supports fatty acid oxidation
Riboflavin: Supports complex I activity
Dichloroacetate: Stimulates PDH activity
N-acetylcysteine: Antioxidant support
These provide partial benefit but do not address the root cause.
Since SUCLA2 deficiency affects nucleotide pools:
Ketogenic Diet: May provide alternative energy substrate
Calorie Restriction: May improve mitochondrial function
Specific Amino Acid Limitation: Reduce succinyl-CoA production from protein
Sucla2 Knockout: Homozygous knockout is embryonic lethal
Heterozygous Mice: Show partial deficiency
Conditional Knockouts: Brain-specific deletion shows:
SUCLA2 interacts with several mitochondrial proteins:
Core Complex:
Metabolic Enzymes:
Mitochondrial Translation:
Quality Control:
SUCLA2 shows tissue-specific expression:
| Tissue | Expression Level | Significance |
|---|---|---|
| Brain | High | Neuronal energy demands |
| Heart | Very High | Continuous contractile function |
| Skeletal Muscle | High | Exercise-induced demands |
| Kidney | Moderate | Metabolic function |
| Liver | Moderate | Metabolic processing |
In the brain:
For SUCLA2-related disease:
Genetic Testing: Sequencing for pathogenic variants
Biochemical Markers:
Functional Assays:
Imaging: